Second-generation versus first-generation drug-eluting stents in saphenous vein graftdisease: A meta-analysis of randomized controlled trials

详细信息    查看全文

• 作者：Hong-tao Shi^a ; ¹ ; Hong-xia Chu^b ; ¹ ; Wei Gu^c ; ¹ ; Xin-yong Cai^d ; ¹ ; Jun-jie Guo^a ; ^e ; ¹ ; Zhao-gang Ding^f ; Wei Gao^a ; Lei-lei Ma^a ; Jian-bing Zhu^a ; Hai-bo Liu^a ; Zhe-yong Huang^a ; Qi-bing Wang^a ; Jun-bo Ge^a ; ^{jbge@zs-hospital.sh.cn" class="auth_mail" title="E-mail the corresponding author} ; Shao-jun Wen^c ; ^{anzhenwensj@sina.com" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Second-generation drug-eluting stent ; First-generation drug-eluting stent ; Meta-analysis ; Saphenous vein grafts
• 刊名：International Journal of Cardiology
• 出版年：2016
• 出版时间：1 July 2016
• 年：2016
• 卷：214
• 期：Complete
• 页码：393-397
• 全文大小：319 K

文摘

Second-generation drug-eluting stents (DESs) have become increasingly popular devices for patients with saphenous vein graft (SVG) disease. Second-generation DESs were designed to have more safety and efficacy than first-generation DES, but clinical outcomes in SVG disease remain conflicting.

Methods and results

Randomized controlled trials (RCTs) were identified when comparing second- versus first-generation DESs in SVG disease. The main endpoint was all-cause death. The time of follow-up was at least 30 days. The secondary endpoints were major adverse cardiovascular events (MACEs), target vessel revascularization (TVR), target lesion revascularization (TLR), myocardial infarction (MI), and stent thrombosis. These endpoints were assessed at 30 days, 12 months and 24 months. Four RCTs with 1077 SVG patients undergoing the implantation of DES were collected in the current meta-analysis. As a result, second-generation DES-treated patients had the significantly lower MACE rates at 12 months (P = 0.03; OR: 0.69, 95% CI: 0.49,0.97). No differences in two groups were seen in all-cause death, MI, TVR, stent thrombosis and TLR.

Conclusions

Our limited evidence indicated that, second-generation DES in SVG patients, compared with first-generation DES, offered similar levels of safety, but were more effective than the former one.